Clinical Development of BRAF plus MEK Inhibitor Combinations: Trends in Cancer
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor | Nature Medicine
Cells | Free Full-Text | LTB4R Promotes the Occurrence and Progression of Clear Cell Renal Cell Carcinoma (ccRCC) by Regulating the AKT/mTOR Signaling Pathway
Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C - ScienceDirect
Genetically manipulating endogenous Kras levels and oncogenic mutations in vivo influences tissue patterning of murine tumorigenesis | eLife